Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Shun Doi
A Phase I Study of Multi-Hla-Binding Peptides Derived From Heat Shock Protein 70/Glypican-3 and a Novel Combination Adjuvant of hLAG-3Ig and Poly-Iclc for Patients With Metastatic Gastrointestinal Cancers: YNP01 Trial
Cancer Immunology, Immunotherapy
Cancer Research
Medicine
Oncology
Allergy
Immunology
Related publications
Vaccination With LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial
Clinical Cancer Research
Cancer Research
Oncology
Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients With Refractory Advanced Cancers
Clinical Cancer Research
Cancer Research
Oncology
Phase I Trial With a Combination of Docetaxel and 153Sm-Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer
Urologic Oncology: Seminars and Original Investigations
Oncology
Urology
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
First-In-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients With Advanced Hepatocellular Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine for Patients With Advanced Pancreatic Cancer
Journal of immunotherapy (Hagerstown, Md. : 1997)
Cancer Research
Allergy
Immunology
Pharmacology
Heat Shock Protein Peptide Complex-96 Vaccination for Newly Diagnosed Glioblastoma: A Phase I, Single-Arm Trial
JCI insight
Medicine
Efficacy and Safety of TAS-116, an Oral Inhibitor of Heat Shock Protein 90, in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumour Refractory to Imatinib, Sunitinib and Regorafenib: A Phase II, Single-Arm Trial
European Journal of Cancer
Cancer Research
Oncology
A Phase I Trial of Combination Trastuzumab, Lapatinib, and Bevacizumab in Patients With Advanced Cancer
Investigational New Drugs
Oncology
Pharmacology
